GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Cyclically Adjusted PS Ratio

Can Fite Biofarma (XTAE:CANF) Cyclically Adjusted PS Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biofarma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted PS Ratio Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.60 1.50 0.92 -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.31 0.44 0.38 -

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PS Ratio falls into.



Can Fite Biofarma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Can Fite Biofarma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Can Fite Biofarma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.013 100.684 0.017
201509 0.011 100.392 0.014
201512 0.004 99.792 0.005
201603 0.008 100.470 0.010
201606 0.007 101.688 0.009
201609 0.008 101.861 0.010
201612 -0.001 101.863 -0.001
201703 0.007 102.862 0.009
201706 0.007 103.349 0.009
201709 0.071 104.136 0.088
201712 0.010 104.011 0.012
201803 0.069 105.290 0.085
201806 0.025 106.317 0.030
201809 0.225 106.507 0.273
201812 0.029 105.998 0.035
201903 0.024 107.251 0.029
201906 0.015 108.070 0.018
201909 0.036 108.329 0.043
201912 0.006 108.420 0.007
202003 0.004 108.902 0.005
202006 0.002 108.767 0.002
202009 0.002 109.815 0.002
202012 0.001 109.897 0.001
202103 0.001 111.754 0.001
202106 0.002 114.631 0.002
202109 0.002 115.734 0.002
202112 0.001 117.630 0.001
202203 0.001 121.301 0.001
202206 0.001 125.017 0.001
202209 0.001 125.227 0.001
202212 0.001 125.222 0.001
202303 0.001 127.348 0.001
202306 0.001 128.729 0.001
202309 0.001 129.860 0.001
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Can Fite Biofarma  (XTAE:CANF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Can Fite Biofarma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (XTAE:CANF) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (XTAE:CANF) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019